Screener / SEC EDGAR /CIK 0001356576 /10-K filed Mar 2, 2026, compared with Feb 25, 2025 /Numbers from the XBRL of the 10-Ks
Health care · Pharmaceuticals

Supernus, Inc. SUPN

Compare with peers Embed
FY2025 at a glance

Sales up 8.6%, free cash flow down to $46.0M

XBRL, from each 10-K
RevenueStatements
$719.0M from $661.8M in FY2024
FY2016FY2025
Net incomeStatements
-$38.5M from $73.9M in FY2024
FY2016FY2025
Free cash flowStatements
$46.0M from $171.2M in FY2024
FY2016FY2025
EPS (diluted)Statements
$-0.68 from $1.32 in FY2024
FY2016FY2025
Operating marginStatements
-8.7% from 12.3% in FY2024
FY2016FY2025

The latest figures

Price and key numbers

From EDGAR
All key numbers (36)
EPS (ttm)
-0.76
Sales (ttm)
865.1M
Net income (ttm)
-43.9M
Sales growth
+8.6%
EPS growth
to a loss
Sales Q/Q
+18.0%
Free cash flow
87.0M
Gross margin
87.6%
Oper. margin
-5.7%
Net margin
-5.1%
FCF margin
10.1%
R&D / sales
14.8%
Dividend
-
Debt/Eq
-
Curr. ratio
2.49
Cash
175.9M
Op. cash flow (ttm)
88.2M
EBITDA
29.3M
EBITDA margin
4.1%
Quick ratio
2.10
FCF after stock pay
12.9M
Goodwill / assets
8.6%
Oper. margin low 5y
-8.7%
Stock pay / sales
4.6%
Shares out.
58.2M
Shares Y/Y
+0.9%
Book / share
18.24
Cash / share
3.02
Sales / share
14.86
Asset turnover
0.62
Inventory turns
0.66
Days sales out.
95
Sales 3Y CAGR
+2.5%
Sales 5Y CAGR
+6.7%

Hover or tap a number to see the XBRL line item and filing it comes from; click it to open that filing at SEC. What each number means. Looks wrong? Tell us.

Revenue and net income, FY2016 to FY2025

Each fiscal year from its own 10-K · XBRL

Revenue 719.0M +14.4% a year Net income -38.5M
FY2016 revenue 215.0M · Revenues, 0001047469-19-000828 FY2016 net income 91.2M · NetIncomeLoss, 0001047469-19-000828 215.0M FY2016 FY2017 revenue 302.2M · Revenues, 0001356576-20-000010 FY2017 net income 57.3M · NetIncomeLoss, 0001356576-20-000010 302.2M FY2017 FY2018 revenue 408.9M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001356576-21-000028 FY2018 net income 111.0M · NetIncomeLoss, 0001356576-21-000028 408.9M FY2018 FY2019 revenue 392.8M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001356576-22-000025 FY2019 net income 113.1M · NetIncomeLoss, 0001356576-22-000025 392.8M FY2019 FY2020 revenue 520.4M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001356576-23-000016 FY2020 net income 127.0M · NetIncomeLoss, 0001356576-23-000016 520.4M FY2020 FY2021 revenue 579.8M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001356576-23-000016 FY2021 net income 53.4M · NetIncomeLoss, 0001356576-23-000016 579.8M FY2021 FY2022 revenue 667.2M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001356576-25-000017 FY2022 net income 60.7M · NetIncomeLoss, 0001356576-25-000017 667.2M FY2022 FY2023 revenue 607.5M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001356576-26-000011 FY2023 net income 1.3M · NetIncomeLoss, 0001356576-26-000011 607.5M FY2023 FY2024 revenue 661.8M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001356576-26-000011 FY2024 net income 73.9M · NetIncomeLoss, 0001356576-26-000011 661.8M FY2024 FY2025 revenue 719.0M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001356576-26-000011 FY2025 net income -38.5M · NetIncomeLoss, 0001356576-26-000011 719.0M FY2025

From XBRL in each 10-K. Hover a bar for the line item and filing. "A year" is the steady yearly growth from FY2016 to FY2025 (9 years).

Growth per share, FY2015 to FY2025

Earnings, book value and free cash flow for each diluted share · 10-K XBRL, every year linked to its filing

Average yearly growth
Book value per share +27.0% a year FY2015 $1.72 to FY2025 $18.81, 10 years
Free cash flow per share -24.4% a year FY2022 $1.89 to FY2025 $0.81, 3 years
Fiscal year toEPS (diluted)Book value / shareFree cash flow / share
Dec 31, 2025 -$0.68$18.81$0.81
Dec 31, 2024 $1.32$18.51$3.06
Dec 31, 2023 $0.02$16.60$1.99
Dec 31, 2022 $1.04$14.37$1.89
Dec 31, 2021 $0.98$15.01-
Dec 31, 2020 $2.36$13.87$2.51
Dec 31, 2019 $2.10$11.06$2.61
Dec 31, 2018 $2.05$8.37$2.37
Dec 31, 2017 $1.08$5.02$2.11
Dec 31, 2016 $1.76$3.71$1.26
Dec 31, 2015 $0.28$1.72$0.63

Per share means per diluted weighted-average share of the same fiscal year (the count under diluted EPS, put on today's share count after a split). Book value is shareholders' equity at the year end, including any preferred stock; free cash flow is operating cash flow less capital spending. Each tile's rate is the steady yearly growth from the first to the last year it names: the window starts at the oldest year, up to ten years back, with a value above zero.

What the balance sheet holds, per share

Net current asset value and tangible book value, FY2025 · 10-K XBRL, no share price used

Net current asset value, FY2025, in dollars
  • + Current assets $644.2M
  • − All liabilities $390.9M
  • = Net current asset value $253.2M
Per share, year by year
Tangible book value, FY2025, in dollars
  • + Shareholders' equity $1.1B
  • − Goodwill $124.9M
  • − Other intangible assets $569.5M
  • = Tangible book value $367.4M
Per share, year by year

Net current asset value is current assets minus all liabilities (the long-term ones too), so it is what would be left from the short-term assets after everything owed is paid; it is blank for a bank, which reports no current assets. Tangible book value is shareholders' equity minus goodwill and other intangible assets; equity includes any preferred stock. Both are divided by the diluted weighted-average share count of the same fiscal year. Red bars are amounts taken off, or a negative result.

SUPN against Health care peers

Among the 162 companies, the better end on the right. The band holds the middle half; the line is the median.

Ten years, side by side
Sales growth
+4.8%+20.2%
+8.6%88th of 155 · median +10.5%
Net margin
-4.1%15.3%
-5.1%118th of 154 · median 6.8%
Return on equity
-5.2%18.5%
-4.1%106th of 144 · median 9.2%
Free cash flow margin
2.3%19.2%
10.1%72nd of 145 · median 10.0%
SUPN and the 5 peers closest in revenue
CompanyRevenue (ttm)Sales growthFYGross marginttmNet marginttmROEttmFCF marginttmDebt / equitylatest
SUPN Supernus, Inc.$865.1M +8.6%87.6%-5.1%-4.1%10.1%-
TGTX TG Therapeutics, Inc.$897.8M +87.3%82.7%11.8%18.5%9.5%1.30
INSP Inspire Medical Systems, Inc.$880.9M +13.6%86.2%11.4%12.2%11.1%-
AXSM Axsome Therapeutics, Inc.$865.3M +65.5%--18.2%-149.2%-9.5%1.78
IRTC iRhythm Holdings, Inc.$854.0M +26.2%72.3%-4.5%-21.8%0.9%-
RGEN Repligen Corp$805.6M +16.4%53.5%-1.5%-0.6%13.2%0.27
All 162 companies in the group

Where each dollar goes

Revenue through the costs to the net profit, from the 10-K income statement

From $667.2M of sales to $60.7M of profit FY2022

Revenue to Gross profit: $580.0MRevenue to Cost of revenue: $87.2MGross profit to Operating profit: $46.1MGross profit to Operating expenses: $533.9MOperating profit to Net profit: $46.1MOther income to Net profit: $14.6MOperating expenses to R&D: $74.6MOperating expenses to Sales, admin & other: $459.3M Revenue: $667.2M REVENUE $667.2M +15% Y/Y Gross profit: $580.0M · 87% margin GROSS PROFIT $580.0M 87% margin Cost of revenue: $87.2M · 13% of revenue COST OF REVENUE $87.2M 13% of revenue Operating profit: $46.1M · 7% margin OPERATING PROFIT $46.1M 7% margin · −46% Y/Y Other income: $14.6M · 2% of revenue OTHER INCOME $14.6M 2% of revenue Operating expenses: $533.9M · 80% of revenue OPERATING EXPENSES $533.9M 80% of revenue Net profit: $60.7M · 9% margin NET PROFIT $60.7M 9% margin · +14% Y/Y R&D: $74.6M · 11% of revenue R&D $74.6M 11% of revenue Sales, admin & other: $459.3M · 69% of revenue SALES, ADMIN & OTHER $459.3M 69% of revenue

From $607.5M of sales to $1.3M of profit FY2023

Revenue to Gross profit: $523.7MRevenue to Cost of revenue: $83.8MGross profit to Net profit: $1.3MGross profit to Costs, tax, other: $522.4M Revenue: $607.5M REVENUE $607.5M −9% Y/Y Gross profit: $523.7M · 86% margin GROSS PROFIT $523.7M 86% margin Cost of revenue: $83.8M · 14% of revenue COST OF REVENUE $83.8M 14% of revenue Net profit: $1.3M · 0% margin NET PROFIT $1.3M 0% margin · −98% Y/Y Costs, tax, other: $522.4M · 86% of revenue COSTS, TAX, OTHER $522.4M 86% of revenue

From $661.8M of sales to $73.9M of profit FY2024

Revenue to Gross profit: $583.9MRevenue to Cost of revenue: $77.9MGross profit to Operating profit: $81.7MGross profit to Operating expenses: $502.2MOperating profit to Net profit: $57.7MOperating profit to Tax: $24.0MOther income to Net profit: $16.2MOperating expenses to R&D: $108.8MOperating expenses to Sales, admin & other: $393.4M Revenue: $661.8M REVENUE $661.8M +9% Y/Y Gross profit: $583.9M · 88% margin GROSS PROFIT $583.9M 88% margin Cost of revenue: $77.9M · 12% of revenue COST OF REVENUE $77.9M 12% of revenue Operating profit: $81.7M · 12% margin OPERATING PROFIT $81.7M 12% margin Other income: $16.2M · 2% of revenue OTHER INCOME $16.2M 2% of revenue Operating expenses: $502.2M · 76% of revenue OPERATING EXPENSES $502.2M 76% of revenue Net profit: $73.9M · 11% margin NET PROFIT $73.9M 11% margin · +5513% Y/Y Tax: $24.0M · 4% of revenue TAX $24.0M 4% of revenue R&D: $108.8M · 16% of revenue R&D $108.8M 16% of revenue Sales, admin & other: $393.4M · 59% of revenue SALES, ADMIN & OTHER $393.4M 59% of revenue

Where each $100 of sales went

FY2022
FY2023
FY2024
  • Cost of revenue
  • Sales, admin & other
  • Net profit
  • R&D
  • Tax, less other income

Band widths are the money. Gross profit is revenue less cost of revenue; operating expenses are gross profit less operating profit; R&D is from the income statement and the rest of the operating expenses is everything else; tax includes interest and other items when they are small. Y/Y is the change from the fiscal year before. Revenue by part only for the years in the last two 10-Ks' segment tables. The full income statement

Where the return on equity comes from

DuPont: net margin × asset turnover × leverage, FY2025 against FY2020 · 10-K XBRL, year-end balances

Return on equity -3.6% FY2020: 17.0% net income ÷ equity
Net margin -5.4% FY2020: 24.4% profit per $ of sales: -38.5M ÷ 719.0M
Asset turnover 0.49× FY2020: 0.35× sales per $ of assets: 719.0M ÷ 1.5B
Leverage 1.37× FY2020: 2.02× assets per $ of equity: 1.5B ÷ 1.1B

The three parts multiply to the return on equity. A higher return from leverage alone means more debt or less equity (buybacks shrink equity), not a better business. Year-end balances as filed, not averages, so each number is one line of one 10-K; hover a box for its XBRL tags.

Profitability

  • Net margin below the peer median
    -5.1% vs 6.8%
  • Return on equity below 15%
    -4.1%
  • A profit in 9 of 10 years
Net margin, FY2016 to FY2025: 42.4% to -5.4%

Cash and shareholders

  • Free cash flow positive in every one of 9 years
    $46.0M last year
  • Share count up over 5 years
    +5.1%
Free cash flow, FY2016 to FY2025: 65.2M to 46.0M

Each tick is a fact with a fixed rule (on /methodology), not a score or advice. A check without the numbers it needs is left out.

Contracted revenue and deferred revenue

Backlog (remaining performance obligations) and cash received in advance, by balance sheet date · XBRL

Contract liabilities

Paid in advance $3.1M cash received before delivery, not yet recognized as revenue, Dec 31, 2025
  • Dec 31, 2025 $3.1M
  • Sep 30, 2025 $0
  • Dec 31, 2024 $0
  • Dec 31, 2023 $0
  • Dec 31, 2022 $0
  • Dec 31, 2021 $0
  • Dec 31, 2020 $0
  • Dec 31, 2019 $0

Both are balance-sheet-date values from the 10-K and 10-Qs. Backlog is what is under contract, not a forecast: contracts can be cancelled or change in size, and a company counts them in its own way. Hover a number for its XBRL line; click it to open the filing.

Income statement, balance sheet and cash flow

Statements · XBRL, each 10-K and 10-Q

From EDGAR

SUPN's income statement, balance sheet and cash flow as reported to the SEC in XBRL, one column per fiscal year, the last 10. Hover a number to see the line item and filing it comes from. Where a company changed how it tags a line, the first tag it reported for that period is used. A number looks wrong? Tell us.

Revenue719.0M
FY2016: 215.0MFY2017: 302.2MFY2018: 408.9MFY2019: 392.8MFY2020: 520.4MFY2021: 579.8MFY2022: 667.2MFY2023: 607.5MFY2024: 661.8MFY2025: 719.0M FY2017FY2019FY2021FY2023FY2025
Net income-38.5M
FY2016: 91.2MFY2017: 57.3MFY2018: 111.0MFY2019: 113.1MFY2020: 127.0MFY2021: 53.4MFY2022: 60.7MFY2023: 1.3MFY2024: 73.9MFY2025: -38.5M FY2017FY2019FY2021FY2023FY2025
Free cash flow46.0M
FY2016: 65.2MFY2017: 112.6MFY2018: 128.1MFY2019: 140.4MFY2020: 134.9MFY2021: -FY2022: 116.4MFY2023: 110.5MFY2024: 171.2MFY2025: 46.0M FY2017FY2019FY2021FY2023FY2025
Free cash flow after stock pay12.9M
FY2016: 59.3MFY2017: 104.2MFY2018: 116.9MFY2019: 125.5MFY2020: 118.4MFY2021: -FY2022: 98.8MFY2023: 83.8MFY2024: 143.5MFY2025: 12.9M FY2017FY2019FY2021FY2023FY2025
EPS (diluted)-0.68
FY2016: 1.76FY2017: 1.08FY2018: 2.05FY2019: 2.10FY2020: 2.36FY2021: 0.98FY2022: 1.04FY2023: 0.02FY2024: 1.32FY2025: -0.68 FY2017FY2019FY2021FY2023FY2025
Diluted shares56.5M
FY2016: 51.7MFY2017: 53.3MFY2018: 54.1MFY2019: 53.8MFY2020: 53.7MFY2021: 54.4MFY2022: 61.7MFY2023: 55.5MFY2024: 56.0MFY2025: 56.5M FY2017FY2019FY2021FY2023FY2025

Revenue by product or service

year to Dec 31, 2025
RevenueSharevs year before
Qelbree 304.7M42.4% +26.3%
GOCOVRI 146.8M20.4% +12.2%
Collaboration revenue (ZURZUVAE) 53.0M7.4% -
APOKYN 47.8M6.6% -35.4%
Trokendi XR 42.4M5.9% -32.9%
Oxtellar XR 40.7M5.7% -59.1%
Royalty, licensing, and other revenues 39.4M5.5% +63.4%
Other 26.9M3.7% -7.2%
ONAPGO 17.3M2.4% -

10-K 0001356576-26-000011, segment and revenue notes (XBRL).

Income statement

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue215.0M302.2M408.9M392.8M520.4M579.8M667.2M607.5M661.8M719.0M
Cost of revenue12.0M15.2M15.4M16.7M52.5M-87.2M83.8M77.9M74.6M
R&D42.8M49.6M89.2M69.1M76.0M90.5M74.6M91.6M108.8M106.2M
SG&A106.0M137.9M154.7M153.2M200.7M304.8M377.2M336.4M321.6M485.6M
Operating income54.2M99.5M144.4M148.6M173.7M86.0M46.1M-5.3M81.7M-62.3M
Interest expense543K134K13.8M18.2M19.4M19.7M7.1M2.4M00
Pretax income50.4M100.6M140.2M147.5M168.6M73.2M60.7M2.8M97.9M-49.0M
Income tax-40.9M43.3M29.2M34.4M41.7M19.8M32K1.5M24.0M-10.5M
Net income91.2M57.3M111.0M113.1M127.0M53.4M60.7M1.3M73.9M-38.5M
EPS (diluted)1.761.082.052.102.360.981.040.021.32-0.68
Diluted shares51.7M53.3M54.1M53.8M53.7M54.4M61.7M55.5M56.0M56.5M
Depreciation & amortization2.4M8.1M7.1M6.7M18.1M32.6M85.5M84.9M80.4M91.6M
EBITDA56.6M107.7M151.5M155.2M191.8M118.6M131.7M79.6M162.1M29.3M
Operating margin25.2%32.9%35.3%37.8%33.4%14.8%6.9%-0.9%12.3%-8.7%
Net margin42.4%19.0%27.1%28.8%24.4%9.2%9.1%0.2%11.2%-5.4%
Revenue growth+45.8%+40.6%+35.3%-3.9%+32.5%+11.4%+15.1%-8.9%+8.9%+8.6%
EPS growth+529%-38.6%+89.8%+2.4%+12.4%-58.5%+6.1%-98.1%+6500%to a loss

Cash flow

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow66.8M114.6M129.0M143.1M138.4M127.1M116.8M111.1M172.0M47.3M
Capital spending1.6M2.0M844K2.7M3.4M-412K551K725K1.3M
Free cash flow65.2M112.6M128.1M140.4M134.9M-116.4M110.5M171.2M46.0M
Stock-based pay (added back)5.9M8.4M11.3M14.8M16.6M17.9M17.6M26.8M27.8M33.1M
Free cash flow after stock pay59.3M104.2M116.9M125.5M118.4M-98.8M83.8M143.5M12.9M
Acquisitions--00298.5M950K000293.1M
Investing cash flow-36.0M-86.4M-413.5M-157.9M-34.7M-81.9M-216.7M268.7M-189.9M4.1M
Financing cash flow2.1M5.7M376.4M3.9M3.6M-130.4M-10.5M-397.9M12.2M9.1M

Stock-based pay and leases

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Stock-based pay (expense)5.9M8.4M11.3M14.8M16.6M17.9M17.6M26.8M27.8M33.1M
Stock-based pay / revenue2.8%2.8%2.8%3.8%3.2%3.1%2.6%4.4%4.2%4.6%
Operating lease cost---6.9M7.5M12.0M12.8M14.3M14.4M15.7M
Operating lease cash paid---5.3M6.9M11.9M12.9M17.1M17.3M18.5M
Finance lease principal paid---0802K0----
Right-of-use assets---21.3M20.2M35.4M28.9M29.0M24.5M26.7M
Operating lease liabilities---33.3M32.3M47.8M42.8M41.5M34.3M41.0M
Finance lease liabilities----24.0M-----

From SEC's XBRL company facts (data.sec.gov). EBITDA = operating income + depreciation and amortization; free cash flow = operating cash flow - capital spending; total debt = long-term debt (with its current part) + short-term borrowings. Stock-based pay and leases are shown as the company reports them; Tickdelta does not take them out of earnings or add leases to debt. Click a number to open the filing in SEC's Inline XBRL viewer, where you can click the same number to see how it is tagged. Values a company later revised show as revised; the Revised numbers tab lists the changes.

Sources

Every figure is from the company's XBRL filed with each 10-K and 10-Q (data.sec.gov). Hover a number for its line item; click it to open the filing.

Also

Company numbers: the figures the company reports beyond the statements. Peers: ten years, side by side.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/SUPN/export.csv") into a cell.

Next:Peers in numbers
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.